A nanobody discovery service can help CAR-T and cell therapy teams identify single-domain antibody candidates against a selected target, then assess whether those candidates are suitable for further engineering and testing. A well-planned project connects target and binder selection to the intended application, such as a CAR recognition domain, a cell-targeting reagent, or a research tool. The discovery result is a starting point—not proof that a nanobody will function safely or effectively in a cell therapy product. At NBbiolab, we work with project teams to define the discovery scope, agree on expected deliverables, and plan validation around the intended use.
If you want to learn more, please visit our website.
This guide is for CAR-T researchers, cell therapy developers, translational scientists, and veterinary medicine teams considering nanobodies for research or development. It is also relevant to procurement and partnering teams comparing custom discovery providers. The appropriate project design depends on the target, species, intended cell type, and stage of development. Teams should align technical goals with their regulatory, biosafety, and quality requirements before commissioning work.
Nanobodies are single-domain antibody fragments derived from heavy-chain-only antibodies found in camelids and related animals. A commonly cited approximate molecular mass for a VHH nanobody is 12–15 kDa, while a conventional IgG antibody is approximately 150 kDa. These are general reference values, not guaranteed specifications for every engineered candidate.
A discovery service typically applies a defined selection and screening strategy to identify binders against a customer’s target. Depending on the agreed scope, the work may include antigen review, library selection or immunization, screening, sequence identification, and preliminary characterization. Teams should ask providers to distinguish planned activities from optional services, because project content varies by platform and contract.
Start by providing the target’s identity, relevant species, and intended use. For CAR-T development, specify whether the nanobody is being explored as a CAR binding domain or for another role in the cell therapy workflow. Share the target format and biological context where possible, including whether the desired epitope should be accessible on intact cells.
Target presentation can shape what a screen finds. A soluble protein may expose surfaces differently from the same target in a membrane, complex, or native cell environment. Discuss these differences with the provider before selecting the screening antigen, and state any known requirements for species cross-reactivity or recognition of particular target variants.
The provider and project team should agree on how candidates will be generated or selected and how initial hits will be screened. A plan might include target-binding assays, counter-screening against related proteins, and testing against cells expressing the target, where suitable materials and methods are available. The precise assays should be selected for the question being asked rather than included simply because they are customary.
For veterinary medicine applications, clarify whether the target is from a companion animal, livestock species, or another relevant species. A binder identified against a human protein should not be assumed to recognize the corresponding veterinary ortholog. If cross-species recognition is needed, define which species and target forms must be evaluated.
After screening, promising hits can be sequenced and assessed against the project’s selection criteria. Depending on the contract, deliverables may include candidate sequences, assay results, ranking rationale, and produced nanobody material for follow-up. Ask whether sequence uniqueness, additional binding characterization, or sequence optimization is included or requires a separate scope.
Candidate prioritization should consider the intended application. Strong binding in a purified-protein assay alone does not establish that a binder recognizes the target on relevant cells or will behave appropriately when incorporated into a CAR. For cell therapy development, the team should plan a staged evaluation that connects biochemical screening to cellular and construct-level testing.
Validation should be designed around the biological claim the team needs to support. Depending on the project, useful follow-up may include confirmation of target-dependent cell binding, assessment of binding to relevant negative-control cells, and evaluation of performance after incorporation into a research-stage CAR construct. The appropriate controls and acceptance criteria should be set by the development team and qualified personnel.
NBbiolab Product Page
Early-stage discovery data do not establish clinical efficacy, safety, manufacturability, or regulatory suitability. Those questions require additional development and evidence appropriate to the product and jurisdiction. For veterinary applications, study design should also reflect the intended animal species and applicable institutional or regulatory requirements.
Service scope can range from discovery alone to discovery plus selected characterization or material production. Before starting, request a written deliverables list that identifies what will be provided, in what format, and at which project stage. This helps prevent confusion between a sequence report, a physical reagent, and a validated cell therapy component.
| Deliverable category | What to clarify |
|---|---|
| Candidate information | Number of sequences, sequence format, and whether prioritization data are included |
| Screening evidence | Target format, assay type, controls, and how results will be reported |
| Physical material | Whether nanobody protein is included, along with agreed quantity, format, and handling information |
| Follow-up support | Availability and scope of further characterization, engineering, or cell-based evaluation |
Ask how the provider will represent the target and whether that format is relevant to the intended application. For a cell-surface target, consider whether screening should include native or cell-presented target material, where feasible. Also discuss target quality, known variants, and the need for counter-screens to distinguish specific recognition from unwanted binding.
Request a clear description of the proposed workflow, decision points, and data package. Ask how candidates are selected for further study and what constitutes a reportable hit under the project plan. A transparent provider should explain limitations as well as capabilities and should not present discovery-stage binding as proof of therapeutic performance.
Before sharing sequences, target information, or proprietary constructs, review confidentiality and intellectual-property terms with the appropriate legal or business stakeholders. Confirm who owns resulting sequences and data, whether materials may be used in downstream development, and whether any restrictions apply. These terms are contract-specific and should not be assumed from a general service description.
Custom discovery pricing and timing depend on factors such as target readiness, species, screening design, assay requirements, and the number of follow-up activities. There is no universal project price, minimum order, or lead time that can be applied to every target. Request a project-specific quotation that separates core discovery from optional validation and production work.
For useful planning, ask the provider to identify required customer inputs, review milestones, decision points, and factors that could affect schedule. Provide target information and application requirements early, and agree how changes to scope will be handled. This makes proposals easier to compare than a single headline price or estimated completion date.
At NBbiolab, we support teams evaluating custom nanobody discovery for CAR-T and broader cell therapy development. We can discuss target suitability, species requirements, screening priorities, expected deliverables, and potential follow-up needs during project planning. Our role is to help define a practical scope; the final validation strategy should remain aligned with your research objectives and development requirements.
A nanobody discovery service can provide candidate binders and supporting evidence for further CAR-T or cell therapy research, but its value depends on a clear target definition, application-matched screening, and appropriately staged validation. Before selecting a provider, compare the workflow, data package, material deliverables, species coverage, intellectual-property terms, and optional follow-up services. Treat early results as a basis for deciding what to test next, not as a substitute for downstream evaluation.
To begin planning with NBbiolab, prepare your target details, intended application, relevant species, preferred target format, and required deliverables. We can use that information to discuss a discovery scope and provide a project-specific proposal for your review.
For more Nanobody Discovery Service for CAR-T and Cell Therapy Developmentinformation, please contact us. We will provide professional answers.